Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.1362 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.1362 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0344 | 0.1843 | 0.1843 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.1362 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0127 | 0.0099 | 0.0099 |
Brugia malayi | hypothetical protein | 0.0278 | 0.1311 | 0.1311 |
Trypanosoma brucei | protein kinase, putative | 0.1362 | 1 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.1362 | 1 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1362 | 1 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0354 | 0.1921 | 0.1921 |
Echinococcus granulosus | ankyrin repeat and death domain containing protein | 0.0114 | 0.000000053205 | 0.000000053205 |
Echinococcus granulosus | mitogen activated protein kinase | 0.1362 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1362 | 1 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.1362 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1362 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1362 | 1 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1362 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.1362 | 1 | 1 |
Echinococcus multilocularis | Ankyrin | 0.0115 | 0.0004 | 0.0004 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.1362 | 1 | 0.5 |
Brugia malayi | Death domain containing protein | 0.0114 | 0.000000053205 | 0.000000053205 |
Echinococcus multilocularis | jun protein | 0.0354 | 0.1921 | 0.1921 |
Schistosoma mansoni | ankyrin 23/unc44 | 0.0114 | 0.000000053205 | 0.000000053205 |
Onchocerca volvulus | 0.0278 | 0.1311 | 1 | |
Schistosoma mansoni | jun-related protein | 0.0288 | 0.1389 | 0.1389 |
Loa Loa (eye worm) | hypothetical protein | 0.0115 | 0.0004 | 0.0004 |
Echinococcus granulosus | jun protein | 0.0354 | 0.1921 | 0.1921 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.1362 | 1 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.1362 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.1362 | 1 | 1 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.1207 | 0.8761 | 0.8761 |
Echinococcus multilocularis | ankyrin repeat and death domain containing protein | 0.0114 | 0.000000053205 | 0.000000053205 |
Brugia malayi | Uncoordinated protein 44 | 0.0114 | 0.000000053205 | 0.000000053205 |
Schistosoma mansoni | retinoblastoma-binding protein 4 (rbbp4) | 0.0115 | 0.0004 | 0.0004 |
Brugia malayi | bZIP transcription factor family protein | 0.0354 | 0.1921 | 0.1921 |
Schistosoma mansoni | hypothetical protein | 0.0288 | 0.1389 | 0.1389 |
Echinococcus granulosus | Ankyrin | 0.0115 | 0.0004 | 0.0004 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.1362 | 1 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.1362 | 1 | 0.5 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.1207 | 0.8761 | 0.8761 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0354 | 0.1921 | 0.1921 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1362 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 12 ug ml-1 | In vitro cytotoxicity was determined against L1210 leukemia cell from mouse. | ChEMBL. | 2299637 |
Survival (functional) | = 37 % | Percent survival of L1210 cells in suspension was determined after a dose of 10 microg/mL in mouse | ChEMBL. | 2299637 |
T/C (functional) | = 103 % | In vivo cytotoxicity was determined against P388 mouse leukemia cells expressed as % treated/control | ChEMBL. | 2299637 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.